Eli Lilly & Co.'s new drug application (NDA) resubmission for the rheumatoid arthritis treatment Olumiant (baracitinib) appears to have done little to assuage the US FDA's first-cycle concerns about the oral JAK inhibitor's thrombosis risk, and the adequacy of the sponsor's dose selection, ahead of an Arthritis Advisory Committee review April 23.
In a briefing document released April 19, FDA said the additional data provided in Lilly's NDA resubmission, which followed...





